EXPERIMENTAL MODELS
Contributor Information
- Name Roland Wolf
- Institute University of Dundee
Tool Details
- Tool name: ERL Mouse
- Tool type: Experimental models
- Tool sub-type: Mouse
- Disease: Drug metabolism
- Model description: Cre Cyp1a1-Knock-In mouse
- Conditional description: Cre
- Genetic background and cross history: Targeting carried out in C57BL/6 ES cells and line maintained by crossing with wild-type C57BL/6, ie CreCyp1a1-KI/+. Targeting strategy available on request.
- Phenotype: The mouse is a.k.a. Cre Cyp1a1-Knock-In mouse. The line is also maintained as heterozygous for the genetic alteration - it is important to note that one copy of the Cyp1a1 gene has been replaced with Cre recombinase, thus the line is also heterozygous for Cyp1a1 (although there are no apparent phenotypic consequences). However, should the line ever become homozygous for Cyp1a1-Cre, the mice would be homozygous null for Cyp1a1, and although such mice would be viable, they may have phenotypic consequences that might interfere and thus it is better to keep the line as heterozygous for Cyp1a1-Cre.
- Zygosity: Homozygous
- Description: A Conditional knockout mouse. Endogenous Cyp1A1 promoter driving Cre recombinase expression. Administration of 3-methylcholanthrene (3MC) results in expression of Cre recombinase and subsequent deletion of floxed P450 oxidoreductase (POR) in target organs (liver or liver and gut depending on 3MC dosage); may be used early in the drug development process to establish role of P450 activity in drug metabolism & disposition in vivo.
- Research area: Cancer; Drug development; Genetics; Metabolism
- Production details: Targeting carried out in C57BL/6 ES cells and line maintained by crossing with wild-type C57BL/6, ie CreCyp1a1-KI/+. Targeting strategy available on request.
- Additional notes: The mouse is a.k.a. Cre Cyp1a1-Knock-In mouse. The line is also maintained as heterozygous for the genetic alteration - it is important to note that one copy of the Cyp1a1 gene has been replaced with Cre recombinase, thus the line is also heterozygous for Cyp1a1 (although there are no apparent phenotypic consequences). However, should the line ever become homozygous for Cyp1a1-Cre, the mice would be homozygous null for Cyp1a1, and although such mice would be viable, they may have phenotypic consequences that might interfere and thus it is better to keep the line as heterozygous for Cyp1a1-Cre.
- For Research Use Only
Target Details
- Target: P450 Oxidoreductase
Application Details
Handling
- Shipping conditions: Embryo/Spermatoza- Dry Ice
Documentation
References
- • Henderson et al. 2015. Biochem J. 465(3):479-88. PMID: 25377919.
- • Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability.
.svg)
Availability: 
.svg)
.svg)
